AU5727000A - Alpha or beta emitters attached to fragments in radioimmunotherapy - Google Patents
Alpha or beta emitters attached to fragments in radioimmunotherapy Download PDFInfo
- Publication number
- AU5727000A AU5727000A AU57270/00A AU5727000A AU5727000A AU 5727000 A AU5727000 A AU 5727000A AU 57270/00 A AU57270/00 A AU 57270/00A AU 5727000 A AU5727000 A AU 5727000A AU 5727000 A AU5727000 A AU 5727000A
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- fab
- patient
- clearing agent
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
- A61K51/1042—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors against T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13863599P | 1999-06-07 | 1999-06-07 | |
| US60138635 | 1999-06-07 | ||
| PCT/US2000/015477 WO2000074729A2 (en) | 1999-06-07 | 2000-06-07 | Alpha or beta emitters to fragments in radioimmunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5727000A true AU5727000A (en) | 2000-12-28 |
Family
ID=22482926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU57270/00A Abandoned AU5727000A (en) | 1999-06-07 | 2000-06-07 | Alpha or beta emitters attached to fragments in radioimmunotherapy |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6667024B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1187637A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004510683A (cg-RX-API-DMAC7.html) |
| AU (1) | AU5727000A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2374001A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000074729A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| CA2422291C (en) * | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| IL159422A0 (en) | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| US7087206B2 (en) * | 2002-04-12 | 2006-08-08 | Pg Research Foundation | Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| WO2004062722A2 (en) * | 2003-01-08 | 2004-07-29 | Sloan Kettering Institute For Cancer Research | Prevention of systemic toxicity during radioimmunotherapy for intravascularly disseminated cancers |
| ES2314272T3 (es) | 2003-01-10 | 2009-03-16 | Millennium Pharmaceuticals, Inc. | Metodos para el diagnostico y el tratamiento del cancer. |
| US7820787B2 (en) | 2003-01-23 | 2010-10-26 | The Regents Of The University Of California | Multi-functional antibodies |
| US7528235B2 (en) | 2003-01-23 | 2009-05-05 | The Regents Of The Univarsity Of California | Multi-functional antibodies |
| US7402385B2 (en) | 2003-02-11 | 2008-07-22 | Albert Einstein College Of Medicine Of Yeshiva University | Radiolabeled antibodies for treatment of tumors |
| US6900507B1 (en) * | 2004-01-07 | 2005-05-31 | Micron Technology, Inc. | Apparatus with silicide on conductive structures |
| US20050247330A1 (en) * | 2004-04-30 | 2005-11-10 | Hp Intellectual Corp. | Liquid presence sensor |
| US7618627B2 (en) | 2004-06-03 | 2009-11-17 | The Regents Of The University Of California | Method of increasing radiation sensitivity by inhibition of beta one integrin |
| US20060018827A1 (en) * | 2004-07-08 | 2006-01-26 | Ekaterina Dadachova | Positron therapy of inflammation, infection and disease |
| AU2008302345A1 (en) * | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
| CA2100709C (en) * | 1992-07-27 | 2004-03-16 | Maurits W. Geerlings | Method and means for site directed therapy |
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| US5580838A (en) * | 1995-06-05 | 1996-12-03 | Patterson; James A. | Uniformly plated microsphere catalyst |
| JPH11507046A (ja) * | 1995-06-07 | 1999-06-22 | イムノメディクス,インコーポレイテッド | 診断剤および治療剤の標的部位への改良された送達方法 |
| WO1998035707A1 (en) * | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
-
2000
- 2000-06-07 AU AU57270/00A patent/AU5727000A/en not_active Abandoned
- 2000-06-07 CA CA002374001A patent/CA2374001A1/en not_active Abandoned
- 2000-06-07 EP EP00942678A patent/EP1187637A2/en not_active Withdrawn
- 2000-06-07 JP JP2001501263A patent/JP2004510683A/ja active Pending
- 2000-06-07 US US09/588,565 patent/US6667024B1/en not_active Expired - Lifetime
- 2000-06-07 WO PCT/US2000/015477 patent/WO2000074729A2/en not_active Ceased
-
2003
- 2003-12-01 US US10/724,397 patent/US7220399B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1187637A2 (en) | 2002-03-20 |
| WO2000074729A3 (en) | 2001-08-09 |
| US20040180001A1 (en) | 2004-09-16 |
| WO2000074729A2 (en) | 2000-12-14 |
| US6667024B1 (en) | 2003-12-23 |
| JP2004510683A (ja) | 2004-04-08 |
| US7220399B2 (en) | 2007-05-22 |
| CA2374001A1 (en) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7220399B2 (en) | Alpha or beta emitters attached to fragments in radioimmunotherapy | |
| RU2664475C1 (ru) | Новые радиоиммуноконъюгаты и их применения | |
| JP3051339B2 (ja) | 治療的抗白血球結合体及び哺乳動物用非経口的注射剤 | |
| Goodwin et al. | Advances in pretargeting biotechnology | |
| US6723318B1 (en) | Targeting of biomolecules | |
| JP5153044B2 (ja) | レセプターに結合する複合体 | |
| EP0251494A2 (en) | Therapeutic or radiodiagnostic compound | |
| CA2223261C (en) | Improved delivery of diagnostic and therapeutic agents to a target site | |
| JPH0564130B2 (cg-RX-API-DMAC7.html) | ||
| Govindan et al. | Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel | |
| AU2005259258A1 (en) | Radionuclides for medical use | |
| EP1507562B1 (en) | Compositions for radioimmunotherapy of brain | |
| Chinol et al. | Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting | |
| JP2004534752A (ja) | 卵黄抗体(igy)からの免疫コンジュゲート、そのコンフェクショニングならびに診断および治療への使用方法 | |
| Bhalgat et al. | Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates | |
| CA2066031C (en) | Methods for reducing non-target retention of immunoconjugates and metabolites thereof | |
| Govindan et al. | Advances in the use of monoclonal antibodies in cancer radiotherapy | |
| Frier | Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer | |
| Sadri et al. | Synthesis and biodistribution studies of iodine‐131 D‐amino acid YYK peptide as a potential therapeutic agent for labeling an anti‐CD20 antibody | |
| Hansen et al. | Labeling of anti-tumor antibodies and antibody fragments with Tc-99m | |
| Lewis et al. | Targeted antibodies and peptides | |
| Rathmann | Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry | |
| RU2795398C2 (ru) | Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория | |
| Siddiqui et al. | Tumor targeting and pharmacokinetics of unmodified and modified F (ab) 2 fragments of an anti-CEA murine monoclonal antibody (Immu-14) | |
| Oriuchi et al. | Antibodies for targeted imaging: Properties and radiolabeling |